Michael Chen

Michael Chen is a senior research scientist at Adaptive Biotechnologies Corp., with extensive experience in biotechnology and cancer research. Michael has held roles ranging from associate scientist at Refuge Biotechnologies to various research associate positions at organizations such as Apeximmune Therapeutics and Revance Therapeutics, contributing to antibody discovery, functional assays, and drug mechanism studies. A key publication includes work on CAR-T cell reprogramming for HER2+ cancers. Michael's educational background includes master's degrees in Biochemistry and Molecular Biology from the University of Southern California and Biotechnology from National Chiao Tung University, along with a bachelor's degree in Chemistry from National Tsing Hua University.